TL;DR
Turn quiet afternoons into listening time
- Thousands of audiobooks, podcasts and originals
- Listen on your phone, tablet or Echo — also offline
- Cancel anytime
The American Geriatrics Society has published a case-based framework for clinicians prescribing obesity medications, including GLP-1 therapies, to older adults. It calls for assessment of function, nutrition and cognition, with attention to frailty, muscle loss, malnutrition and dehydration.
The American Geriatrics Society (AGS) has published a case-based framework to help clinicians prescribe obesity medications to older adults with attention to age-related health risks. The paper applies the society’s Geriatrics 5Ms approach to incretin therapies, including GLP-1 medicines, and recommends assessing patients’ function, nutrition and cognition before treatment.
Published in the Journal of the American Geriatrics Society, the paper is titled “Obesity Medications in Older Adults: A Geriatrics 5Ms Framework for Safe and Patient-Centered Prescribing.” It was developed by the AGS Healthy Aging Special Interest Group and organizes practical prescribing considerations around clinical cases.
The framework asks clinicians to consider Mind, Mobility, Medications, Multicomplexity and Matters Most. The authors highlight possible concerns for older patients, including frailty, sarcopenia, loss of lean muscle, malnutrition and dehydration. They recommend pretreatment assessment of functional status, nutritional adequacy and cognitive impairment.
The paper also emphasizes support alongside medication. Its authors recommend pairing treatment with measures such as resistance training and adequate dietary protein. For some patients, they say a team that includes a registered dietitian, physical therapist, fitness trainer and behavioral health professional may be appropriate.
Reducing Risks During Weight-Loss Treatment
The framework addresses a practical gap as clinicians consider obesity medicines for older patients: the benefits of treatment need to be weighed against health factors that can affect strength, nutrition and day-to-day function. The paper says older adults are underrepresented in clinical trials, leaving less evidence specific to this group than clinicians may want when making individual treatment decisions.
By putting function, mobility and patients’ own priorities alongside medication choices, the 5Ms approach encourages prescribing decisions to account for more than weight or blood sugar alone. The recommendations also draw attention to the need to monitor for potential problems such as lean-muscle loss, poor nutrition and dehydration. This is a clinical framework, not evidence that every older adult should take these drugs or that the suggested co-interventions eliminate risks.
Products Worth Considering
Oral-B iO Series 3 Rechargeable Electric Toothbrush for Adults, Black
Garmin Forerunner 570 GPS Running Smartwatch, 47mm, Aluminum, Black
Oral-B iO Series 5 Rechargeable Electric Toothbrush with Travel Case, White
As an affiliate, we earn on qualifying purchases.
A Geriatrics Lens on Incretin Therapy
The framework focuses on obesity medications, including GLP-1 medicines that act through gut-derived hormonal pathways. The source report describes potential benefits for weight management, glycemic control and other health conditions, while also noting the limited representation of older adults in trials.
The AGS 5Ms framework provides the paper’s organizing structure: Mind, Mobility, Medications, Multicomplexity and Matters Most. Rather than treating age as a stand-alone prescribing rule, the framework prompts clinicians to consider a person’s capabilities, other health conditions and priorities. The article appeared in the Journal of the American Geriatrics Society in 2026; its DOI is 10.1111/jgs.70769.
“Safe prescribing requires pretreatment assessment of functional status, nutritional adequacy and cognitive impairment.”
— The American Geriatrics Society framework authors, as summarized by Medical Xpress
Evidence Gaps and Individual Risks
The published report does not provide trial results establishing how well the framework improves outcomes, nor does it quantify medication risks for particular older-adult groups. It notes that older people are underrepresented in clinical trials, but the source material does not specify the size of that evidence gap or how it varies by medication.
The framework also does not prescribe one treatment plan for every patient. Which medicine, if any, is suitable, and what monitoring or support a person needs, will depend on individual health and circumstances. The available report does not give detailed dosing guidance, monitoring schedules or estimates of how often complications occur.
How Clinicians May Apply the Framework
The paper’s immediate contribution is a case-based clinical framework for applying the 5Ms to incretin therapy. Clinicians can use its proposed assessments and co-interventions when discussing treatment, while weighing each patient’s function, nutritional status, cognition and goals.
The source material does not announce a formal implementation program, a follow-up study or a timeline for further guidance. Further research that includes more older adults could help clarify how benefits and risks vary across this population. Until then, the paper’s recommendations provide a structured way to consider prescribing, but do not replace individualized clinical judgment.
Key Questions
What did the American Geriatrics Society publish?
The AGS published a case-based framework for clinicians considering obesity medications in older adults, including incretin therapies such as GLP-1 medicines.
What are the Geriatrics 5Ms?
The five areas are Mind, Mobility, Medications, Multicomplexity and Matters Most. The framework uses them to structure patient-centered prescribing considerations.
What should clinicians assess before treatment?
The authors recommend checking functional status, nutritional adequacy and cognitive impairment, while considering factors such as frailty, muscle loss and dehydration.
Does the paper recommend these medicines for every older adult?
No. The framework is intended to guide individual clinical decisions. It does not say that every older adult should use obesity medication or provide a single treatment plan for all patients.
What support does the framework suggest alongside medication?
It recommends measures including resistance training and adequate dietary protein. The authors say some patients may benefit from a team that includes nutrition, physical therapy, fitness and behavioral health professionals.
Source: medicalxpress.com
